Mirae Asset Global Investments Co. Ltd. Makes New Investment in Twist Bioscience Corporation $TWST

Key Points

• Mirae Asset Global Investments initiated a position in Twist Bioscience, buying 29,561 shares worth approximately $5.7 million in the third quarter.
• Analyst views are mixed: seven rate the stock Buy, three Hold and two Sell, yielding a consensus Hold rating and an average price target of $153.
• Twist shares were reported down 15.4%. Its latest quarterly revenue rose 23.2% year over year and topped estimates, while its per-share loss was wider than analysts expected.

Mirae Asset Global Investments Co. Ltd. purchased a new position in Twist Bioscience Corporation (NASDAQ:TWST - Free Report) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 29,561 shares of the company's stock, valued at approximately $5,712,000.

A number of other hedge funds have also recently made changes to their positions in TWST. Root Financial Partners LLC bought a new stake in Twist Bioscience during the 3rd quarter valued at about $33,000. Signaturefd LLC boosted its position in Twist Bioscience by 94.3% in the 3rd quarter. Signaturefd LLC now owns 548 shares of the company's stock valued at $106,000 after buying an additional 266 shares during the period. Allworth Financial LP purchased a new stake in Twist Bioscience in the 2nd quarter valued at about $62,000. Trifecta Capital Advisors LLC bought a new position in Twist Bioscience in the 2nd quarter worth about $63,000. Finally, Western Wealth Management LLC bought a new position in Twist Bioscience in the 1st quarter worth about $31,000.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Canaccord Genuity Group raised their target price on shares of Twist Bioscience from $120.00 to $205.00 and gave the stock a "buy" rating in a research report on Monday, October 12th. Leerink Partners boosted their price target on Twist Bioscience from $160.00 to $190.00 and gave the company an "outperform" rating in a report on Tuesday, September 29th. Barclays boosted their price target on Twist Bioscience from $112.00 to $215.00 and gave the company an "overweight" rating in a report on Wednesday, October 7th. Robert W. Baird increased their price objective on Twist Bioscience from $113.00 to $115.00 and gave the stock an "outperform" rating in a research note on Tuesday, August 4th. Finally, BWS Financial restated a "sell" rating and set a $45.00 price objective on shares of Twist Bioscience in a report on Friday, September 18th. Seven equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat.com, Twist Bioscience currently has a consensus rating of "Hold" and an average price target of $153.00.

Twist Bioscience Stock Down 15.4%

Shares of Twist Bioscience stock opened at $120.61 on Friday. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38. Twist Bioscience Corporation has a 1 year low of $23.30 and a 1 year high of $219.71. The firm's 50-day moving average is $152.00 and its two-hundred day moving average is $90.68. The stock has a market cap of $7.56 billion, a price-to-earnings ratio of -54.33 and a beta of 2.25.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last posted its earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.05). Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. The business had revenue of $118.38 million for the quarter, compared to analysts' expectations of $114.55 million. During the same period last year, the business posted $0.33 EPS. The company's revenue for the quarter was up 23.2% on a year-over-year basis. As a group, research analysts expect that Twist Bioscience Corporation will post -2.12 earnings per share for the current fiscal year.

Insider Buying and Selling at Twist Bioscience

In related news, insider Dennis Cho sold 9,514 shares of the business's stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $188.88, for a total value of $1,797,004.32. Following the completion of the transaction, the insider owned 63,789 shares of the company's stock, valued at $12,048,466.32. The trade was a 12.98% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 10,088 shares of the company's stock in a transaction on Friday, October 2nd. The stock was sold at an average price of $188.88, for a total value of $1,905,421.44. Following the sale, the senior vice president owned 106,632 shares of the company's stock, valued at approximately $20,140,652.16. This represents a 8.64% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 608,597 shares of company stock valued at $94,672,268 in the last ninety days. Company insiders own 3.08% of the company's stock.

More Twist Bioscience News

Here are the key news stories impacting Twist Bioscience this week:

• Positive Sentiment: Twist Bioscience has launched MRD Express, a development that could support its presence in the minimal residual disease testing market. The article also notes the stock is entering earnings week, when investors may look for updates on the product and business outlook. Read More.
• Neutral Sentiment: A separate analysis describes an “undervalued” investment narrative but flags the company’s sales valuation as expensive, presenting a mixed view rather than a clear near-term catalyst. Read More.
• Neutral Sentiment: Four executives and insiders, including CEO Emily M. Leproust, sold a combined 6,677 shares at $135.40. The transactions were reported as covering tax withholding obligations related to equity-award vesting, which makes them less indicative of discretionary selling.
• Negative Sentiment: Shares fell amid a negative report from The Bear Cave/Hunterbrook. The available headline does not detail the report’s claims, but the coverage appears to have weighed on investor sentiment. Read More.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA and related products for life sciences research. The company uses a proprietary silicon-based platform to produce high-quality DNA at scale, supporting applications in synthetic biology, drug discovery and development, agriculture, and academic and industrial research.

Its offerings include synthetic genes, oligonucleotides, gene fragments, variant libraries, and antibody discovery products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.